Your browser doesn't support javascript.
loading
Genetic Concordance in Primary Cutaneous Melanoma and Matched Metastasis: A Systematic Review and Meta-Analysis.
Kerkour, Thamila; Zhou, Catherine; Hollestein, Loes; Mooyaart, Antien.
Afiliação
  • Kerkour T; Department of Dermatology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
  • Zhou C; Department of Dermatology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
  • Hollestein L; Department of Dermatology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
  • Mooyaart A; Department of Pathology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Int J Mol Sci ; 24(22)2023 Nov 14.
Article em En | MEDLINE | ID: mdl-38003476
ABSTRACT
Studying primary melanoma and its corresponding metastasis has twofold benefits. Firstly, to better understand tumor biology, and secondly, to determine which sample should be examined in assessing drug targets. This study systematically analyzed all the literature on primary melanoma and its matched metastasis. Following PRISMA guidelines, we searched multiple medical databases for relevant publications from January 2000 to December 2022, assessed the quality of the primary-level studies using the QUIPS tool, and summarized the concordance rate of the most reported genes using the random-effects model. Finally, we evaluated the inter-study heterogeneity using the subgroup analysis. Thirty-one studies investigated the concordance of BRAF and NRAS in 1220 and 629 patients, respectively. The pooled concordance rate was 89.4% [95% CI 84.5; 93.5] for BRAF and 97.8% [95% CI 95.8; 99.4] for NRAS. When high-quality studies were considered, only BRAF mutation status consistency increased. Five studies reported the concordance status of c-KIT (93%, 44 patients) and TERT promoter (64%, 53 patients). Lastly, three studies analyzed the concordance of cancer genes involved in the signaling pathways, apoptosis, and proliferation, such as CDKN2A (25%, four patients), TP53 (44%, nine patients), and PIK3CA (20%, five patients). Our study found that the concordance of known drug targets (mainly BRAF) during melanoma progression is higher than in previous meta-analyses, likely due to advances in molecular techniques. Furthermore, significant heterogeneity exists in the genes involved in the melanoma genetic makeup; although our results are based on small patient samples, more research is necessary for validation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article